MX2013008868A - Nuevas azaindolifenil sulfonamidas como inhibidores de serina/treonina cinasa. - Google Patents

Nuevas azaindolifenil sulfonamidas como inhibidores de serina/treonina cinasa.

Info

Publication number
MX2013008868A
MX2013008868A MX2013008868A MX2013008868A MX2013008868A MX 2013008868 A MX2013008868 A MX 2013008868A MX 2013008868 A MX2013008868 A MX 2013008868A MX 2013008868 A MX2013008868 A MX 2013008868A MX 2013008868 A MX2013008868 A MX 2013008868A
Authority
MX
Mexico
Prior art keywords
azaindolylphenyl
sulfonamides
serine
new
kinase inhibitors
Prior art date
Application number
MX2013008868A
Other languages
English (en)
Spanish (es)
Inventor
Heinz Stadtmueller
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2013008868A publication Critical patent/MX2013008868A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2013008868A 2011-02-02 2012-02-02 Nuevas azaindolifenil sulfonamidas como inhibidores de serina/treonina cinasa. MX2013008868A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11153087 2011-02-02
EP11181258 2011-09-14
PCT/EP2012/051796 WO2012104388A1 (en) 2011-02-02 2012-02-02 New azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2013008868A true MX2013008868A (es) 2013-08-14

Family

ID=45558742

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008868A MX2013008868A (es) 2011-02-02 2012-02-02 Nuevas azaindolifenil sulfonamidas como inhibidores de serina/treonina cinasa.

Country Status (15)

Country Link
US (1) US8889684B2 (OSRAM)
EP (1) EP2670749B1 (OSRAM)
JP (1) JP5850952B2 (OSRAM)
KR (1) KR20140014149A (OSRAM)
CN (1) CN103476773A (OSRAM)
AU (1) AU2012213390A1 (OSRAM)
BR (1) BR112013019714A2 (OSRAM)
CA (1) CA2825279A1 (OSRAM)
CL (1) CL2013002063A1 (OSRAM)
EA (1) EA201300874A1 (OSRAM)
IL (1) IL227399A0 (OSRAM)
MX (1) MX2013008868A (OSRAM)
PH (1) PH12013501618A1 (OSRAM)
UY (1) UY33890A (OSRAM)
WO (1) WO2012104388A1 (OSRAM)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008001943A1 (es) 2007-07-02 2009-09-11 Boehringer Ingelheim Int Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
AR073501A1 (es) 2008-09-08 2010-11-10 Boehringer Ingelheim Int Derivados de pirimido[5,4-d]pirimidina inhibidores de la tirosinoquinasa
US8778929B2 (en) 2008-09-29 2014-07-15 Boehringer Ingelheim International Gmbh Substituted heteroaryl inhibitors of B-RAF
JP5603883B2 (ja) 2009-02-17 2014-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング B−Rafキナーゼを阻害するためのピリミドピリミジン誘導体
BR112012002854B1 (pt) 2009-08-10 2020-02-18 Samumed, Llc Composto ou sal farmaceuticamente aceitável, composição farmacêutica e uso dos mesmos
WO2011084486A1 (en) 2009-12-21 2011-07-14 Epitherix, Llc 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
WO2011117382A1 (en) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh Pyridyltriazoles
JP5871896B2 (ja) 2010-03-26 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング B−rafキナーゼインヒビター
WO2011146313A1 (en) 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
US8889684B2 (en) 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
AU2012308570B2 (en) 2011-09-14 2016-11-10 Samumed, Llc Indazole-3-carboxamides and their use as Wnt/b-catenin signaling pathway inhibitors
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
RU2689141C2 (ru) 2012-05-04 2019-05-24 СЭМЬЮМЕД, ЭлЭлСи 1н-пиразоло[3,4-b]пиридины и их терапевтические применения
CN104302627A (zh) 2012-05-22 2015-01-21 北卡罗来纳大学教堂山分校 用于治疗癌症的嘧啶化合物
WO2014062774A1 (en) 2012-10-17 2014-04-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
US9771330B2 (en) 2012-11-27 2017-09-26 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
CN105120862A (zh) 2013-01-08 2015-12-02 萨穆梅德有限公司 Wnt信号途径的3-(苯并咪唑-2-基)-吲唑抑制剂及其治疗应用
CA2906523A1 (en) * 2013-03-15 2014-09-25 Myriad Genetics, Inc. Genes and gene signatures for diagnosis and treatment of melanoma
US20150291606A1 (en) 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Mertk-specific pyrrolopyrimidine compounds
EP4250299A3 (en) 2014-07-02 2023-12-06 Myriad myPath, LLC Genes and gene signatures for diagnosis and treatment of melanoma
WO2016040182A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
WO2016040185A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040188A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040190A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040193A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
CA2964282C (en) * 2014-10-27 2023-03-07 University Health Network Ripk2 inhibitors and method of treating cancer with same
WO2017024010A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
US10519169B2 (en) 2015-08-03 2019-12-31 Samumed, Llc 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10226448B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
WO2017023986A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017023989A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10166218B2 (en) 2015-08-03 2019-01-01 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10350199B2 (en) 2015-08-03 2019-07-16 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017023984A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
US10226453B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10329309B2 (en) 2015-08-03 2019-06-25 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10206909B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10231956B2 (en) 2015-08-03 2019-03-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10285982B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017023972A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023975A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
WO2017023996A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US10188634B2 (en) 2015-08-03 2019-01-29 Samumed, Llc 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
CN107531710B (zh) * 2015-08-13 2020-02-14 北京韩美药品有限公司 Irak4抑制剂及其应用
EP3370721A4 (en) 2015-11-06 2019-05-22 Samumed, LLC TREATMENT OF OSTEOARTHRITIS
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
SG11201810683VA (en) 2016-06-01 2018-12-28 Samumed Llc Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide
MX391624B (es) 2016-10-21 2025-03-04 Samumed Llc Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina.
KR102558716B1 (ko) 2016-11-07 2023-07-21 사뮤메드, 엘엘씨 단일-투여량, 즉시-사용가능한 주사용 제제
PL3689868T3 (pl) 2016-12-01 2024-03-11 Arvinas Operations, Inc. Pochodne tetrahydronaftalenu i tetrahydroizochinoliny jako degradery receptorów estrogenowych
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
CN117510491A (zh) * 2016-12-23 2024-02-06 阿尔维纳斯运营股份有限公司 用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法
MY203853A (en) * 2017-10-26 2024-07-22 Xynomic Pharmaceuticals Inc Crystalline salts of a b-raf kinase inhibitor
MX2022002415A (es) 2019-08-26 2022-03-22 Arvinas Operations Inc Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos.
JP2023539663A (ja) 2020-08-28 2023-09-15 アルビナス・オペレーションズ・インコーポレイテッド 急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法
BR112023004656A2 (pt) 2020-09-14 2023-05-09 Arvinas Operations Inc Formas cristalinas e amorfas de um composto para a degradação direcionada do receptor de estrogênio
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
CN115010574B (zh) * 2022-06-06 2024-01-05 爱斯特(成都)生物制药股份有限公司 1-溴-2-氯-4-氟-2碘苯的合成方法
WO2024054591A1 (en) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ510587A (en) * 1998-09-18 2003-11-28 Abbott Gmbh & Co 4-aminopyrrolopyrimidines as kinase inhibitors
BR0014073A (pt) * 1999-09-17 2002-07-16 Abbott Gmbh & Co Kg Pirazolopirimidinas como agentes terapêuticos
DE60306193T2 (de) 2002-11-27 2006-10-12 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield 1,2,3-triazolamid-derivate als cytokininhibitoren
CA2535896A1 (en) * 2003-08-21 2005-03-10 Osi Pharmaceuticals, Inc. N-substituted benzimidazolyl c-kit inhibitors
EP1692116B1 (en) 2003-12-03 2011-03-09 Boehringer Ingelheim Pharmaceuticals Inc. 1,2,3-triazole amide derivatives as inhibitors of cytokine production
ES2389203T3 (es) * 2004-01-12 2012-10-24 Ym Biosciences Australia Pty Ltd Inhibidores de quinasa selectivos
CA2557856C (en) 2004-03-09 2010-06-29 Boehringer Ingelheim Pharmaceuticals, Inc. 3-'4-heterocyclyl-1,2,3,-triazol-1-yl!-n-aryl-benzamides as inhibitors of the cytokines production for the treatment of chronic inflammatory diseases
US7485657B2 (en) 2004-05-12 2009-02-03 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
US20060004197A1 (en) * 2004-07-02 2006-01-05 Thomas Thrash Sulfonamide-based compounds as protein tyrosine kinase inhibitors
US7531560B2 (en) 2004-11-10 2009-05-12 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
JP2007076376A (ja) 2005-09-09 2007-03-29 Yanmar Co Ltd トラクタ
GB0526246D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
US7858804B2 (en) 2006-04-18 2010-12-28 Boehringer Ingelheim International Gmbh Process for making cytokine inhibiting compounds containing 4- and 5-imidazolyl rings and the intermediates thereof
UA95298C2 (ru) 2006-07-07 2011-07-25 Бьёрингер Ингельхайм Интернациональ Гмбх Фенилзамещенные гетероарильные производные и их применение в качестве противоопухолевых средств
CL2008001943A1 (es) 2007-07-02 2009-09-11 Boehringer Ingelheim Int Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
CA2692379A1 (en) 2007-07-02 2009-01-08 Boehringer Ingelheim International Gmbh Antiproliferative compounds based on 5-membered heterocycles
BRPI0814423B1 (pt) * 2007-07-17 2022-04-19 Plexxikon, Inc Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos
PL2215094T3 (pl) * 2007-11-15 2016-09-30 Związki heterocykliczne zawierające n
US8778929B2 (en) 2008-09-29 2014-07-15 Boehringer Ingelheim International Gmbh Substituted heteroaryl inhibitors of B-RAF
WO2010042337A1 (en) 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
TW201041888A (en) * 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
JP2013503188A (ja) * 2009-08-28 2013-01-31 アレイ バイオファーマ、インコーポレイテッド Raf阻害化合物およびその使用方法
JP5871896B2 (ja) 2010-03-26 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング B−rafキナーゼインヒビター
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
US8546443B2 (en) 2010-12-21 2013-10-01 Boehringer Ingelheim International Gmbh Benzylic oxindole pyrimidines
US20130023531A1 (en) 2011-01-27 2013-01-24 Boehringer Ingelheim International Gmbh Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors
US8889684B2 (en) 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors

Also Published As

Publication number Publication date
US8889684B2 (en) 2014-11-18
JP2014504622A (ja) 2014-02-24
CL2013002063A1 (es) 2013-12-27
JP5850952B2 (ja) 2016-02-03
IL227399A0 (en) 2013-09-30
WO2012104388A1 (en) 2012-08-09
PH12013501618A1 (en) 2013-09-30
KR20140014149A (ko) 2014-02-05
UY33890A (es) 2012-08-31
US20130029993A1 (en) 2013-01-31
EP2670749B1 (en) 2016-01-27
AU2012213390A1 (en) 2013-08-01
CN103476773A (zh) 2013-12-25
CA2825279A1 (en) 2012-08-09
BR112013019714A2 (pt) 2016-10-18
EA201300874A1 (ru) 2014-02-28
EP2670749A1 (en) 2013-12-11

Similar Documents

Publication Publication Date Title
MX2013008868A (es) Nuevas azaindolifenil sulfonamidas como inhibidores de serina/treonina cinasa.
CO6640285A2 (es) 5-alquinil-pirimidinas
DOP2014000062A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
UY33817A (es) ?nuevas oxindolpirimidinas bencílicas?.
ECSP15008851A (es) Compuestos heteroaromáticos como inhibidores de btk
ECSP13012448A (es) Nuevas aminopirazoloquinazolinas.
ECSP14013215A (es) Compuestos novedosos
UY38712A (es) Lactamas fusionadas de arilo y heteroarilo
MX2012003101A (es) Derivados de pirimidina como inhibidores de la proteina tirosina quinasa 2.
MX2015015738A (es) Derivados del bipirazol como inhibidores de janus cinasa (jak).
MX2017002656A (es) Compuestos que inhiben la proteína mcl-1.
CR20150326A (es) Inhibidores de autotaxina
UY35827A (es) Derivados de triazolopirazina como inhibidores de la proteína brd4
MX2016014547A (es) Compuestos para tratar atrofia muscular espinal.
PE20151023A1 (es) Triazolopirazinas
UY35129A (es) Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina
ECSP16074478A (es) Compuestos novedosos
ECSP11011558A (es) Nuevos compuestos químicos.
NI201500096A (es) Compuesto químicos
UY32009A (es) 5-alquinil-pirimidinas
CO6290768A2 (es) Tiazolil-dihidro-indazoles
CO6460762A2 (es) 5-alquinil-piridinas
CO6592046A2 (es) 5-alquinil pirimidas y su uso como inhibidores de quinasa
ECSP11011464A (es) Tia-triaza-ciclopentazulenos
UY33816A (es) ?nuevas triazolilfenil sulfonamidas como inhibidores de serina/treonina cinasa?.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal